Manager TitleAgeSince
Director of Finance/CFO 59 2020-05-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 69 2014-11-03
Director/Board Member 61 2014-08-31
Director/Board Member 48 2021-08-30
Date Insider Type Main position Quantity % Market Cap.
4/3/25 Issuer sale

Chief Financial Officer

350,663 0.9263%
4/3/25 Issuer sale

Director

228,552 0.6037%
4/3/25 Issuer sale

Director

33,948 0.0897%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 221M
+2.13%+2.23%-17.54%+0.29% 183B
-0.08%+0.25%-3.85%+2.24% 110B
+2.46%+4.09%+14.53%+75.37% 61.72B
+0.80%+7.66%+37.39%+53.59% 54.98B
+3.76%+7.02%+2.70%-34.61% 47.02B
-5.88%-11.78% - - 32.16B
+0.44%+11.38%+8.66%-31.01% 31.19B
-0.69%+2.65%+46.92%-7.06% 24.7B
-0.40%+0.25%+4.78%+2.55% 22.68B
Average +0.25%+2.66%+11.70%+7.67% 63.05B
Weighted average by Cap. +0.97%+2.70%+1.84%+9.69%
Logo Nevro Corp.
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Employees
1,099
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NVRO Stock